Impact of TP53 Mutations on Survival Outcomes in Large B-Cell Lymphoma

195 adult patients with relapsed/refractory large B-cell lymphoma were analyzed to compare survival outcomes between CAR-T therapy and chemotherapy-based treatments. The dataset, created by Rui Liu and last updated in June 2026, includes 75 patients (38%) with TP53 mutations and tracks objective response rates and median overall survival. Results indicate CAR-T therapy was associated with significantly improved outcomes for both TP53-mutated and wild-type patients compared to chemotherapy.

Use Cases

• Compare overall survival (OS) and progression-free survival (PFS) between CAR-T and chemotherapy cohorts based on treatment modality.
• Analyze the prognostic impact of TP53 mutation type (missense vs. disruptive) and protein domain (DBD vs. non-DBD) on treatment response.
• Investigate the relationship between TP53 mutation status and the incidence of CAR-T-related toxicities like cytokine release syndrome.
• Model survival outcomes for patients with r/r LBCL based on mutational status and therapeutic intervention.

Strengths

• Includes detailed clinical outcomes for 195 patients, with 151 receiving CAR-T therapy and 44 receiving chemotherapy.
• Provides specific survival metrics, such as a median OS of 12.13 months for TP53-mutated patients on CAR-T vs. 2.20 months on chemotherapy.
• Mutational architecture is evaluated, including mutation type and protein domain localization for the 75 TP53-mutant patients.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single retrospective study of 195 patients, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective analysis of 195 adult patients with r/r LBCL who underwent Next-Generation Sequencing (NGS).

Freshness

Last updated 2026-06-03 06:06:57; freshness should be verified.